Key Points
- CFO Kory James Wentworth sold 7,988 shares on March 4 at an average of $12.25 (about $97,853), lowering his stake by 5.47% to 137,987 shares, with the transaction disclosed on an SEC Form 4.
- Shares rose about 8.3% to $12.58 on heavy trading (465,481 shares vs. a ~194,515 average), valuing the company at roughly $481.6 million and near its 52‑week high.
- Entrada reported a narrower-than-expected quarterly loss of $0.94 per share (vs. a $1.32 consensus) but revenue missed materially at $1.3M vs. $7.41M, the company remains unprofitable, and analysts are mixed with a consensus "Moderate Buy" and an average target of $18.50.
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) CFO Kory James Wentworth sold 7,988 shares of the firm's stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $12.25, for a total value of $97,853.00. Following the completion of the transaction, the chief financial officer directly owned 137,987 shares in the company, valued at $1,690,340.75. The trade was a 5.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Entrada Therapeutics Stock Up 8.3%
Shares of Entrada Therapeutics stock traded up $0.96 during trading hours on Friday, reaching $12.58. 465,481 shares of the stock traded hands, compared to its average volume of 194,515. Entrada Therapeutics, Inc. has a one year low of $4.93 and a one year high of $12.93. The firm has a market capitalization of $481.56 million, a price-to-earnings ratio of -3.64 and a beta of -0.12. The company has a 50 day moving average price of $11.05 and a 200 day moving average price of $8.69.
Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.94) earnings per share for the quarter, topping the consensus estimate of ($1.32) by $0.38. Entrada Therapeutics had a negative net margin of 565.48% and a negative return on equity of 39.83%. The firm had revenue of $1.30 million for the quarter, compared to analysts' expectations of $7.41 million. Sell-side analysts anticipate that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current year.
Hedge Funds Weigh In On Entrada Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State of Wyoming grew its holdings in Entrada Therapeutics by 130.9% during the 2nd quarter. State of Wyoming now owns 7,575 shares of the company's stock valued at $51,000 after buying an additional 4,295 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Entrada Therapeutics by 72.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company's stock worth $51,000 after acquiring an additional 3,707 shares in the last quarter. Occudo Quantitative Strategies LP purchased a new stake in shares of Entrada Therapeutics during the 2nd quarter worth approximately $68,000. IHT Wealth Management LLC bought a new position in shares of Entrada Therapeutics during the 2nd quarter valued at approximately $72,000. Finally, AXQ Capital LP bought a new position in shares of Entrada Therapeutics during the 3rd quarter valued at approximately $67,000. 86.39% of the stock is owned by institutional investors.
Trending Headlines about Entrada Therapeutics
Here are the key news stories impacting Entrada Therapeutics this week:
- Positive Sentiment: HC Wainwright reiterated a "Buy" rating and maintained a $20.00 price target on TRDA, which signals meaningful upside from current levels and likely supported buying interest. HC Wainwright note
- Positive Sentiment: HC Wainwright nudged its Q1 2026 EPS estimate to a smaller loss (from ($1.20) to ($1.12)), a modest improvement that can be read as slightly better near‑term expectations for operating performance. HC Wainwright note
- Neutral Sentiment: Short‑interest data reported a jump claim but shows 0 shares short (short‑interest ratio 0.0 days); this appears to be a data anomaly. If accurate, near‑zero reported short interest reduces downward short‑pressure, but the feed’s inconsistency makes this point uncertain. Short interest report
- Negative Sentiment: HC Wainwright cut several near‑term EPS forecasts (Q2–Q4 2026 and FY2026 lowered; FY2026 moved to ($4.49) from ($4.21)) and trimmed multiple 2026/2027 quarterly EPS views, signaling larger expected losses in the near term. Deteriorating near‑term profitability expectations could pressure the stock if operational or cash‑burn concerns persist. HC Wainwright note
Analyst Upgrades and Downgrades
A number of brokerages recently issued reports on TRDA. Oppenheimer began coverage on Entrada Therapeutics in a research note on Wednesday, January 28th. They set an "outperform" rating and a $21.00 price objective for the company. Wall Street Zen upgraded shares of Entrada Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, February 28th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Entrada Therapeutics in a report on Monday, December 29th. HC Wainwright restated a "buy" rating and issued a $20.00 price objective on shares of Entrada Therapeutics in a research report on Wednesday, February 18th. Finally, Guggenheim raised Entrada Therapeutics to a "strong-buy" rating in a research note on Wednesday, February 11th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Entrada Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $18.50.
View Our Latest Stock Analysis on TRDA
Entrada Therapeutics Company Profile
(
Get Free Report)
Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.
The company's pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
